Prescription medicine
Ticagrelor Brand names: Brilinta
Ticagrelor (Brilinta) is a prescription medicine with an FDA approval on record since 2011. FDA's NDC Directory lists it from 28 generic labelers, and pharmacies paid $0.253 per ticagrelor 90 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
- Boxed warning
Check it at the source: the ticagrelor FDA label on DailyMed (effective May 7, 2026, AstraZeneca Pharmaceuticals LP); the NDA 22433 record on Drugs@FDA; every ticagrelor label on DailyMed.
Highlights of the record
FDA label of May 7, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
BLEEDING RISK • BRILINTA,.
like other antiplatelet agents, can cause significant, sometimes fatal bleeding ( 5.1 , 6.1 ).
Do not use BRILINTA in patients with active pathological bleeding or a history of intracranial hemorrhage
( 4.1 , 4.2 ).
Do not start BRILINTA in patients undergoing urgent coronary artery bypass graft surgery (CABG) ( 5.1 ,
6.1 ).
If possible, manage bleeding without discontinuing BRILINTA. Stopping BRILINTA increases the risk of
subsequent cardiovascular events ( 5.2 ). WARNING: BLEEDING RISK See full prescribing information for complete boxed warning.
BRILINTA, like other antiplatelet agents, can cause significant,
sometimes fatal bleeding. ( 5.1 , 6.1 )
Do not use BRILINTA in patients with active pathological
bleeding or a history of intracranial hemorrhage. ( 4.1 , 4.2 )
Do not start BRILINTA in patients undergoing urgent coronary
artery bypass graft surgery (CABG). ( 5.1 , 6.1 )
If possible, manage bleeding without discontinuing BRILINTA.
Stopping BRILINTA increases the risk of subsequent
cardiovascular events.
Used for
From the label: indications and usageBRILINTA is a P2Y 12 platelet inhibitor indicated
to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI.
Forms and strengths
- 60 mg
- 90 mg
Tablet; film-coated tablet.
On the market
- Earliest approval on file
- July 20, 2011 Brilinta, Astrazeneca; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 21 first September 4, 2018; 20 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 30 of which 28 under generic applications, 3 under brand applications, repackagers included
- Last listed patent
- July 27, 2036 Brilinta tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $0.253 per tablet Ticagrelor 90 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 2 since 2017 1 Class I among all firms' recalls; latest March 15, 2021
- FAERS reports
- 31,712 through July 30, 2026
What is ticagrelor used for?
From the label: indications and usageBRILINTA is a P2Y 12 platelet inhibitor indicated
to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1)
to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of BRILINTA was established in a population with type 2 diabetes mellitus (T2DM). […]
Conditions named in the indications of ticagrelor's FDA labels, with every medicine labeled for each:
From other ticagrelor labelsStroke prevention: Stroke or Transient Ischemic Attack (TIA) BRILINTA is indicated to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA) [see Clinical Studies (14.3) ].
FDA pharmacologic class: P2Y12 Platelet Inhibitor.
Source: FDA drug label (BRILINTA), AstraZeneca Pharmaceuticals LP, effective May 7, 2026 (SPL set f7b3f443-e83d-4bf2-0e96-023448fed9a8), via openFDA; the full label on DailyMed
What does the patient leaflet for ticagrelor say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about BRILINTA?BRILINTA is used to lower your chance of having, or dying from, a heart attack or stroke. BRILINTA (and similar drugs) can cause bleeding that can be serious and sometimes lead to death. In cases of serious bleeding, such as internal bleeding, the bleeding may result in the need for blood transfusions or surgery. While you take BRILINTA: • you may bruise and bleed more easily • you are more likely to have nose bleeds • it will take longer than usual for any bleeding to stop Call your healthcare provider right away, if you have any of these signs or symptoms of bleeding while taking BRILINTA: • bleeding that is severe or that you cannot control • pink, red or brown urine • vomiting blood or your vomit looks like “coffee grounds” • red or black stools (looks like tar) • coughing up blood or blood clots Do not stop taking BRILINTA without talking to the healthcare provider who prescribes it for you. People who are treated with a stent, and stop taking BRILINTA too soon, have a higher risk of getting a blood clot in the stent, having a heart attack, or dying. If you stop BRILINTA because of bleeding, or for other reasons, your risk of a heart attack or stroke may increase. Your healthcare provider may instruct you to stop taking BRILINTA 5 days before surgery. This will help to decrease your risk of bleeding with your surgery or procedure. Your healthcare provider should tell you when to start taking BRILINTA again, as soon as possible after surgery. Taking BRILINTA with aspirin BRILINTA is taken with aspirin, unless your healthcare provider specifically tells you otherwise. Talk to your healthcare provider about the dose of aspirin that you should take with BRILINTA. In most cases, you should not take a dose of aspirin higher than 100 mg daily. […]
From the patient leaflet: How should I store BRILINTA?Store BRILINTA at room temperature between 68°F to 77°F (20°C to 25°C). Keep BRILINTA and all medicines out of the reach of children.
Source: FDA drug label (BRILINTA), AstraZeneca Pharmaceuticals LP, effective May 7, 2026 (SPL set f7b3f443-e83d-4bf2-0e96-023448fed9a8), via openFDA; the full label on DailyMed
Is there a generic for ticagrelor (Brilinta)?
The FDA approved the first generic ticagrelor on September 4, 2018. 21 generic applications are approved; 20 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale. Drugs@FDA also holds 1 tentative approval: the FDA found the generic approvable, but patents or exclusivity keep it from final approval for now.
FDA's NDC Directory lists ticagrelor from 28 labelers under a generic (ANDA) application and from 3 brand labelers. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
The Orange Book lists 2 patents for Brilinta tablets, the last expiring on July 27, 2036. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2011 earliest approval on file
- 2018 first generic approved
- 2036 last listed patent
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for ticagrelor (Brilinta)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.253 per Ticagrelor 90 mg tablet, down 43% from $0.445 on October 8, 2025. The survey records the price, not the reason for a change; large moves often follow a new generic or a list-price change. Prices per unit in the table differ many-fold by strength, form and brand, so compare like with like. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Ticagrelor 90 mg tablet (generic)
- Brilinta 90 mg tablet (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Ticagrelor 60 mg tablet | Generic | $0.282 per tablet | $8.46 | -95% |
| Ticagrelor 90 mg tablet | Generic | $0.253 per tablet | $7.59 | -43% |
| Brilinta 60 mg tablet | Brand | $7.42 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $222.57 | -0.1% |
| Brilinta 90 mg tablet | Brand | $7.42 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $222.61 | no change |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has ticagrelor been recalled?
The FDA's Enforcement Report lists 2 recalls naming ticagrelor since 2017: 1 Class I (the most serious), 1 Class II, 0 Class III; 0 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| March 15, 2021 | Class II | Cardinal Health Inc. | CGMP Deviations: Intermittent exposure to temperature excursion during storage. |
| May 25, 2017 | Class I | AstraZeneca Pharmaceuticals, LP | Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 … |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the ticagrelor label say about other medicines?
The ticagrelor label names 18 other medicines in its interaction, contraindication or warning sections. The labels of 18 other medicines name ticagrelor. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Atazanavir | drug interactions | Avoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin) [see Clinical Pharmacology (12.3) ]. |
| Carbamazepine | drug interactions | Avoid use with strong inducers of CYP3A (e.g., rifampin, phenytoin, carbamazepine and phenobarbital) [see Clinical Pharmacology (12.3) ]. |
| Clarithromycin | drug interactions | Avoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin) [see Clinical Pharmacology (12.3) ]. |
| Digoxin | drug interactions | Digoxin BRILINTA inhibits the P-glycoprotein transporter; monitor digoxin levels with initiation of or change in BRILINTA therapy [see Clinical Pharmacology (12.3) ]. |
| Heparin | warnings and precautions | Laboratory Test Interference: False negative platelet functional test results have been reported for Heparin Induced Thrombocytopenia (HIT). |
| Itraconazole | drug interactions | Avoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin) [see Clinical Pharmacology (12.3) ]. |
| Ketoconazole | drug interactions | Avoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin) [see Clinical Pharmacology (12.3) ]. |
| Lovastatin | drug interactions | Patients receiving more than 40 mg per day of simvastatin or lovastatin may be at increased risk of statin-related adverse effects. |
| Morphine | drug interactions | Consider the use of a parenteral anti-platelet agent in acute coronary syndrome patients requiring co-administration of morphine or other opioid agonists. |
| Nefazodone | drug interactions | Avoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin) [see Clinical Pharmacology (12.3) ]. |
| Nelfinavir | drug interactions | Avoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin) [see Clinical Pharmacology (12.3) ]. |
| Phenobarbital | drug interactions | Avoid use with strong inducers of CYP3A (e.g., rifampin, phenytoin, carbamazepine and phenobarbital) [see Clinical Pharmacology (12.3) ]. |
| Phenytoin | drug interactions | Avoid use with strong inducers of CYP3A (e.g., rifampin, phenytoin, carbamazepine and phenobarbital) [see Clinical Pharmacology (12.3) ]. |
| Rifampin | drug interactions | Avoid use with strong inducers of CYP3A (e.g., rifampin, phenytoin, carbamazepine and phenobarbital) [see Clinical Pharmacology (12.3) ]. |
Every other medicine the ticagrelor label names
| Medicine named | Section | What the label says |
|---|---|---|
| Ritonavir | drug interactions | Avoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin) [see … |
| Rosuvastatin | drug interactions | Rosuvastatin plasma concentrations may increase. Monitor for statin-related adverse effects. |
| Simvastatin | drug interactions | Patients receiving more than 40 mg per day of simvastatin or lovastatin may be at increased risk of statin-related adverse effects. |
| Voriconazole | drug interactions | Avoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin) [see … |
Other labels that name ticagrelor
Source: FDA drug label (BRILINTA), AstraZeneca Pharmaceuticals LP, effective May 7, 2026 (SPL set f7b3f443-e83d-4bf2-0e96-023448fed9a8), via openFDA; the full label on DailyMed
What do FAERS reports show for ticagrelor?
The FDA Adverse Event Reporting System holds 31,712 reports that list ticagrelor among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 3,436 are coded as a death and 12,112 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as ticagrelor?
2 other medicines are given the same way (oral) and in the same FDA class as ticagrelor or labeled mainly for the same use (heart attack and coronary artery disease), the same class first. Heart attack and coronary artery disease lists all 38 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Clopidogrel | Heart attack and coronary artery disease | 35 labelers | $0.0472 per tablet 75 mg tablet | No current entry |
| Prasugrel | Heart attack and coronary artery disease | 10 labelers | $0.263 per tablet 10 mg tablet | No current entry |
Every medicine labeled for the same conditions as ticagrelor
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does ticagrelor compare with medicines for the same use?
3 side-by-side pages set ticagrelor beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to ticagrelor
- 2 medicines for the same use
- Other p2y12 inhibitors
- the pharmacologic class, with prices and generics
- Ticagrelor side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other